Melinta Therapeutics, Inc. (MLNT): Price and Financial Metrics

Melinta Therapeutics, Inc. (MLNT): $0.44

0.06 (-12.00%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add MLNT to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked


in industry

MLNT Price/Volume Stats

Current price $0.44 52-week high $10.10
Prev. close $0.50 52-week low $0.31
Day low $0.31 Volume 1,107,200
Day high $0.46 Avg. volume 785,675
50-day MA $1.50 Dividend yield N/A
200-day MA $3.17 Market Cap 6.05M

MLNT Stock Price Chart Interactive Chart >


Melinta Therapeutics, Inc. (MLNT) Company Bio


Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.


MLNT Latest News Stream


Event/Time News Detail
Loading, please wait...

MLNT Latest Social Stream


Loading social stream, please wait...

View Full MLNT Social Stream

MLNT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -70.27%
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -86.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!